What top creators are saying about Eli Lilly and Company(LLY)— Page 3

Included in long positions alongside IBB

Mentioned as a potential acquirer or major player through its direct-to-consumer initiative LillyDirect.

Smashed earnings this week and represents one of the author's biggest stock positions.

Reported Q2 2026 earnings beating estimates with revenue of $23.0B and adjusted EPS of $8.38, and raised full-year 2026 guidance.

Delivered a strong revenue beat driven by surging demand for its class-leading drug portfolio, serving as a stable healthcare holding.

Considered a strong long-term investment due to high demand for weight loss and metabolic drugs like RETRA-2, supported by robust R&D spending and NVIDIA-powered AI drug discovery.

Driving massive success in the pharmaceutical sector behind GLP-1 weight-loss drugs.

Announced plans to officially file for regulatory approval of its oral retatrutide drug in the first quarter of 2027.

Using AI to accelerate drug discovery, resulting in an unnatural competitive advantage and positioning the company to outpace peers.

Viewed as an AI trade due to the intersection of AI and healthcare/drug discovery.

Identified as a target for investors rotating capital into high-quality software/product names.

Facing disruption risk from biologics due to the Black Box Warning and lack of durable effect after treatment cessation for Olumiant.

Part of the high-growth GLP-1 market moving toward oral delivery and combination therapies for weight loss and inflammation.

Described as a decade-long trade based on consumer biotech demand.

Monopoly on GLP-1 patents and effectively using AI for drug modeling; viewed as a rotation hedge with high-conviction buy status.

Healthcare leader expected to benefit from AI application layer productivity gains.

Highlighted as an early adopter using AI agents to drive productivity and improve profit margins.

Specific pharma leader noted for being ripe for AI-driven disruption.

Building a $1 billion AI lab in San Francisco in partnership with NVIDIA to accelerate drug discovery.

Identified as the primary 'AI Pharma' play due to its data-driven approach to drug development.

Acquired Centessa; targeting the Orexin pathway for neuroscience, which could be as transformative as their GLP-1 weight-loss drugs.

Acquired Centessa Pharmaceuticals; leading the bullish sentiment around Orexin pathway drugs.

Predicted to become the largest global company driven by GLP-1/GLP-3 drugs and AI-accelerated discovery.

Positioned as a key beneficiary in the current AI market rotation cycle

High conviction pick due to the 'Obesity Trade' and the upcoming Retatrutide drug catalyst.

Top stock pick for the year with a massive regulatory capture advantage in the AI-meets-health space.

Identified as a key player in the emerging AI-meets-Pharma investment theme.

Strong long position due to expanding use cases for weight loss drugs in treating cancer and dementia.

The federal push for 'deprescribing' and reducing long-term reliance on SSRIs and psychiatric drugs poses a significant threat to prescription volumes and the maintenance-based business model.

The company's medications are now offered on the HIMS platform, effectively functioning as a partnership to expand reach for Tirzepatide.

Primary beneficiary of AI-driven biology breakthroughs and the intersection of AI and biotech.

Partnered with HIMS to distribute weight loss products, providing a significant growth catalyst.

Acting as the 'application layer' for AI in biology; utilizing massive cash flows for AI-driven genetic science.

Using GLP-1 revenues to fund AI-driven biological breakthroughs and a 1,000 GPU data center for drug discovery.

Viewed as a core portfolio anchor with potential for 2x-3x returns; currently overextended, so pullbacks to moving averages are preferred entry points.

Core portfolio anchor and long-term buy and hold; using massive cash flow to build AI data centers for drug trial data.

High-conviction trade in the weight loss/peptide sector with significant growth trajectory.

The market leader with superior current technology (Tirzepatide) and a strong triple-pathway drug (Retatrutide) in development, though the stock carries a high valuation premium.

Visser views LLY as the leader of the AI application layer, utilizing specialized models and Blackwell GPUs to drive ROI in healthcare.

Positioned as the top AI application play using proprietary clinical data and NVIDIA Blackwell GPUs to program biological responses.

Dominant player in the transformative GLP-1 sector; drugs show universal efficacy and address 200+ chronic diseases.

Clear growth trajectory driven by weight loss and healthcare trends; a favorite in the sector.

Positioned to benefit from AI integration in the healthcare sector.

Included in the healthcare sector theme expected to benefit from AI drug development.

Products related to Eli Lilly's GLP-1 weight loss drugs are a key growth lever for the telehealth space despite previous market skepticism.

Strong position in the weight-loss drug market disrupting consumer goods.

Galloway suggests a 'Long GLP-1' strategy, believing the drugs are underhyped and revolutionary for treating obesity and addictive behaviors.

Accelerating revenue growth and deep integration of AI supercomputing to transform drug discovery economics.

Referred to as 'AI Pharma' with strong gains linked to the broader tech/AI market strength.

Viewed as a bio-compute play due to massive GPU power holdings.